Developing a broad and differentiated portfolio of drug candidates to address unmet needs within and beyond psychiatry
Psychiatry
Our psychiatric pipeline features novel combination drug therapies to address the significant shortcomings of current treatment approaches
| Program | Indication | Phase I | Phase II | Phase II | Phase I | Milestone |
|---|---|---|---|---|---|---|
| ELE-Ket+ | Adjunctive Treatment of Major Depressive Disorder | Phase I/II Initiation Q4 2021 | ||||
| ELE-Psilo+ | Adjunctive Treatment of Major Depressive Disorder | Phase I/II Initiation Q1 2022 | ||||
Beyond Psychiatry
Our pipeline of drug candidates extends beyond psychiatry, and includes promising preclinical and clinical-stage drug candidates which harness the anti-inflammatory and disease modifying potential of targeted serotonin 5-HT2A receptor therapies
| Program | Indication | Phase I | Phase II | Phase II | Phase I | Next Milestone |
|---|---|---|---|---|---|---|
| ELE-02 | Ocular Inflammation | Phase I Initiation Q1 2023 | ||||
| ELE-LSD | Alzheimer’s Disease | Phase Ib Exploratory Study Q4 2021 | ||||
| ELE-XX | Peripheral Inflammatory Disease | Discovery | Lead Candidate Identification Q4 2021 | |||